Perioperative Thrombotic Risk Guide for Hematology Fellows
Chokri Ben Lamine, Adult Hematology and Stem Cell Transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital & Research Center, shared a post on X:
“Perioperative Thrombotic Risk – Quick Guide for Hema Fellows
High Risk (>10%/mo VTE or >10%/yr ATE)
Recent (<3 mo) VTE
Strong thrombophilia (Protein C/S def., ATIII def., homozygous FVL/PGM, multiple thrombophilias)
APS
High-risk cancer: pancreas, brain, stomach, esophagus, myeloproliferative
AF: CHA₂DS₂-VASc ≥7, recent (<3 mo) stroke/TIA, rheumatic valve
Mechanical valve: MVR w/ major stroke RF, caged-ball/tilting-disc (any position), recent stroke/TIA
Moderate Risk (4–10%/mo VTE or 4–10%/yr ATE)
VTE within 3–12 mo
Recurrent VTE
Non-strong thrombophilia (heterozygous FVL/PGM)
Non-high-risk cancer VTE
AF: CHA₂DS₂-VASc 5–6
Mechanical valve: MVR w/o major stroke RF, bileaflet AVR w/ major stroke RF
Low Risk (<4%/mo VTE or <4%/yr ATE)
VTE >12 mo ago
AF: CHA₂DS₂-VASc 1–4
Mechanical valve: bileaflet AVR w/o major stroke RF
MCQ
Q: A 65-year-old with AF (CHA₂DS₂-VASc = 6) and VTE 8 months ago is scheduled for elective surgery. Perioperative thrombotic risk?
A) High
B) Moderate
C) Low
Answer: B) Moderate
Explanation: CHA₂DS₂-VASc = 6 → moderate AFib risk; VTE within 3–12 months → moderate VTE risk.
OSCE Scenario
Station: Pre-op anticoagulation planning for high-risk VTE
Prompt: 55-year-old with recent (<3 mo) DVT on warfarin, elective colectomy scheduled.
Tasks:
Identify thrombotic risk category (High)
Discuss bridging anticoagulation plan with LMWH
Outline timing for last LMWH dose before surgery and restart post-op
Counsel on bleeding vs thrombosis risk
Key points for examiner:
Recognize high risk → needs bridging
Stop warfarin 5 days pre-op
Last therapeutic LMWH 24 h pre-op
Credits to ASH SAP 9th edition ”
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals